Cymbalta
Product Images NDC 21695-145

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 21695-145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label (146)

Cymbalta 60mg DR Capsules packaging label showing 30 capsules. Contains duloxetine hydrochloride equivalent to 60mg duloxetine. Label includes lot and expiration placeholders, NDC 21695-146-30. Distributed by Physician Partner, Thousand Oaks, CA, manufactured by Eli Lilly and Company, Indianapolis, IN.*

FDA Label Image

Structural Formula (Cymbalta 01)

Chemical structure diagram of the active ingredient in Cymbalta, depicting its molecular framework including benzene and thiophene rings with a hydrochloride group attached.*

FDA Label Image

Figure 1 (Cymbalta 02)

A line graph showing the percentage of patients improved across different percent improvements in pain from baseline. Four groups are compared: Cymbalta 60 mg BID, Cymbalta 60 mg QD, Cymbalta 20 mg QD, and placebo. The vertical axis represents the percentage of patients improved, and the horizontal axis indicates the percent improvement in pain from baseline.*

FDA Label Image

Figure 2 (Cymbalta 03)

A line graph comparing the percentage of patients improved against the percent improvement in pain from baseline for Cymbalta 60 mg taken twice daily (BID), Cymbalta 60 mg once daily (QD), and a placebo. The x-axis represents percent improvement in pain from baseline from 0 to 100%, and the y-axis represents the percentage of patients improved from 0 to 100%. The chart includes vertical reference lines at 30%, 50%, and 70% pain improvement.*

FDA Label Image

Figure 3 (Cymbalta 13)

A line chart showing the percentage of patients improved versus percent improvement in pain from baseline for Cymbalta 60mg twice daily, Cymbalta 60mg once daily, and placebo groups. The graph compares the efficacy of two dosing regimens of Cymbalta against placebo in terms of patient pain improvement.*

FDA Label Image

Figure 4 (Cymbalta 14)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline for Cymbalta (CYM) at doses of 20 mg, 60 mg, and 120 mg once daily, compared to placebo. The graph indicates higher patient improvement percentages with Cymbalta doses relative to placebo across various levels of pain improvement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.